Skip to content
Screener

Common Stock at other companies

Eli Lilly logo
Eli LillyLLY
$588M-0.7%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$0-100%
uniQure logo
uniQureQURE
$4.09M+25.7%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$81K+3.8%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
200M0.0%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$27K0.0%

Other financials

Income statement

See full
Revenue$3.6M
Gross profit$3.5M
Operating income-$130.5M+3.3%
Net income-$127.6M-2.8%
EPS (diluted)-$0.68+5.6%

Balance sheet

See full
Cash & equivalents$204.6M+41.8%
Total debt$37.7M-21.4%
Total equity$835.2M-18.7%
Total assets$1.2B-0.7%

Cash flow

See full
Operating cash flow-$97.0M-28.8%
CapEx$805.0K-81.2%
Free cash flow-$97.8M-22.9%

Valuation

See full
Market cap$3.92B+88.3%
Enterprise value$3.76B+89.0%
P/S1,089×+1,084×

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-54.9%+34.3pp
Debt / equity0.0×
Current ratio8.4×-1.9×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValueOutstanding.

The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:08 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001714899-26-000097
Line itemJune 30, 2026December 31, 2025
Commitments and contingencies (Note 10)
Stockholders' equity:
Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025
Common stock, $0.01 par value; 400,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 159,755,526 shares and 156,182,177 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively1,9241,888
Additional paid-in capital3,142,7473,062,715
Accumulated other comprehensive income (loss)(1,969)682
Accumulated deficit(2,307,524)(2,051,524)
Total stockholders' equity835,1781,013,761

Item 1. Financial Statements (Unaudited)

FAQ

What is Denali Therapeutics Inc.'s common stock?
Denali Therapeutics Inc. (DNLI) reported common stock of $1.92M in Q2 2026.
How has Denali Therapeutics Inc.'s common stock changed year-over-year?
Denali Therapeutics Inc.'s common stock increased by 7.9% year-over-year, from $1.78M to $1.92M.
What is the long-term trend for Denali Therapeutics Inc.'s common stock?
Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s common stock has grown at a 4.3% compound annual growth rate (CAGR), from $1.53M to $1.89M.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Denali Therapeutics Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude